Deep inside the brains of Huntington disease patients, an immune alarm system meant to protect against infection keeps firing long after the threat is gone—and researchers at Florida Atlantic University have now found a way to quiet it. In a new study published in Proceedings of the National Academy of Sciences, scientists discovered that blocking a molecular pathway known as cGAS-STING significantly reduced brain inflammation, protected neurons, and improved movement in a humanized mouse model of Huntington disease, suggesting a strikingly simpler path forward for treating this devastating genetic disorder.
Huntington disease is a rare, inherited brain disorder caused by a mutation in the huntingtin gene that progressively destroys nerve cells, leading to worsening movement, cognitive and psychiatric symptoms. The disease is fatal and affects coordination, memory, mood and the ability to think clearly. Today, treatments can help manage symptoms, but there are currently no therapies that slow or stop disease progression. Increasing evidence points to chronic brain inflammation as a major contributor to the condition.
The cGAS-STING pathway is part of the body's built-in immune defense system. Its role is to detect damaged or misplaced DNA inside cells—something that can occur during infection, stress or disease—and trigger inflammation to protect the body. The process begins when a protein called cGAS senses abnormal DNA inside a cell and produces a signaling molecule called cGAMP, which activates another protein known as STING. Once activated, STING triggers inflammatory and immune-response genes. While this response is important for fighting infections, excessive activation can lead to chronic inflammation and cellular damage. Researchers have previously linked overactive cGAS-STING signaling to several disorders, including cancer, diabetes, Alzheimer's disease, and ALS. Previous studies also found unusually high levels of cGAS activity in Huntington disease brains and cells, though its role in disease progression remained unclear until now.
To investigate, the Florida Atlantic University researchers genetically removed cGAS in a humanized Huntington disease mouse model and monitored the mice over time. The results were striking: mice lacking cGAS showed marked improvements in motor coordination and balance, including better performance on movement and walking tests. The mice also experienced less body-weight loss as the disease progressed. Examinations of brain tissue revealed substantially lower levels of inflammation in key regions affected by Huntington disease. Researchers observed reduced activation of microglia and astrocytes—immune and support cells in the brain that become overactive during neurodegeneration. The mice showed less shrinkage of the striatum, a brain region heavily damaged in Huntington disease, along with greater preservation of neurons. Further analyses revealed that blocking cGAS restored healthier patterns of gene activity linked to brain signaling and cellular communication.
In a second phase of the study, scientists tested a drug called H-151, which inhibits STING, a downstream component of the same immune pathway. The treatment similarly improved motor performance, reduced brain atrophy and lowered inflammatory activity in the Huntington disease mice.
What makes this finding particularly significant is the simplicity it offers. According to the research team, current Huntington disease therapies largely focus on lowering huntingtin protein levels, but many of these approaches are complex, expensive and difficult to scale because they also risk reducing the healthy version of the protein needed for normal brain function. By contrast, targeting the cGAS-STING pathway offers a potentially simpler strategy that addresses the underlying inflammation without those same risks. The pathway represents not just a new therapeutic target, but a fundamentally different approach to slowing a disease that has long resisted straightforward treatment.